TAKING STOCK
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Millwall is performing better in the stock market than on the football pitch. Its shares gained 0.25p to 4p, highest for more than two years.
The progress has been scored despite persistent selling by director, Jose Berardo. On Thursday he unloaded 1.5 million shares at 3.625p. He has cut his interest to 2.92 per cent (10 million shares) from 12.5 per cent earlier this year.
The strength of the shares could indicate outside stake building. There has also been talk of an assets injection.
Alizyme, the drug tiddler which arrived in July, has experienced a difficult market life. The flotation price was cut to 55p, a level not seen since. The shares fell 11.7 per cent to 37.5p, equalling their low.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments